These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38878767)

  • 41. Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins.
    Furtado JD; Wedel MK; Sacks FM
    J Lipid Res; 2012 Apr; 53(4):784-91. PubMed ID: 22301884
    [TBL] [Abstract][Full Text] [Related]  

  • 42. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.
    Alexander VJ; Xia S; Hurh E; Hughes SG; O'Dea L; Geary RS; Witztum JL; Tsimikas S
    Eur Heart J; 2019 Sep; 40(33):2785-2796. PubMed ID: 31329855
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Compound heterozygosity for a known (D250N) and a novel (E410K) missense mutation in the C-terminal domain of lipoprotein lipase causes familial chylomicronemia.
    Wiebusch H; Funke H; Bruin T; Bucher H; von Eckardstein A; Kastelein JJ; Assmann G
    Hum Mutat; 1996; 8(4):381-3. PubMed ID: 8956048
    [No Abstract]   [Full Text] [Related]  

  • 44. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Gouni-Berthold I; Alexander VJ; Yang Q; Hurh E; Steinhagen-Thiessen E; Moriarty PM; Hughes SG; Gaudet D; Hegele RA; O'Dea LSL; Stroes ESG; Tsimikas S; Witztum JL;
    Lancet Diabetes Endocrinol; 2021 May; 9(5):264-275. PubMed ID: 33798466
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.
    Qamar A; Khetarpal SA; Khera AV; Qasim A; Rader DJ; Reilly MP
    Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1880-8. PubMed ID: 26069232
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Monogenic hypertriglyceridemia and recurrent pancreatitis in a homozygous carrier of a rare APOA5 mutation: a case report.
    Makhmudova U; Schulze PC; Lorkowski S; März W; Geiling JA; Weingärtner O
    J Med Case Rep; 2024 Jun; 18(1):278. PubMed ID: 38872171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pancreatitis risk in genetic subtypes of multifactorial chylomicronemia syndrome.
    Berberich AJ; Hegele RA
    Atherosclerosis; 2024 May; 392():117528. PubMed ID: 38594114
    [No Abstract]   [Full Text] [Related]  

  • 48. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.
    Gordts PL; Nock R; Son NH; Ramms B; Lew I; Gonzales JC; Thacker BE; Basu D; Lee RG; Mullick AE; Graham MJ; Goldberg IJ; Crooke RM; Witztum JL; Esko JD
    J Clin Invest; 2016 Aug; 126(8):2855-66. PubMed ID: 27400128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Familial chylomicronemia and multifactorial chylomicronemia.
    Muñiz-Grijalvo O; Diaz-Diaz JL
    Clin Investig Arterioscler; 2021 May; 33 Suppl 2():56-62. PubMed ID: 34006355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Apolipoprotein C-II deficiency with no rare variant in the APOC2 gene.
    Takase S; Osuga J; Fujita H; Hara K; Sekiya M; Igarashi M; Takanashi M; Takeuchi Y; Izumida Y; Ohta K; Kumagai M; Nishi M; Kubota M; Masuda Y; Taira Y; Okazaki S; Iizuka Y; Yahagi N; Ohashi K; Yoshida H; Yanai H; Tada N; Gotoda T; Ishibashi S; Kadowaki T; Okazaki H
    J Atheroscler Thromb; 2013; 20(5):481-93. PubMed ID: 23470567
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Familial chylomicronemia].
    Quiroga-Padilla PJ; Gaete PV; Mendivil CO
    Medicina (B Aires); 2020; 80(4):348-358. PubMed ID: 32841138
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.
    Hegele RA; Berberich AJ; Ban MR; Wang J; Digenio A; Alexander VJ; D'Erasmo L; Arca M; Jones A; Bruckert E; Stroes ES; Bergeron J; Civeira F; Witztum JL; Gaudet D
    J Clin Lipidol; 2018; 12(4):920-927.e4. PubMed ID: 29748148
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Roundtable on etiology of familial chylomicronemia syndrome.
    Brown WV; Gaudet D; Goldberg I; Hegele R
    J Clin Lipidol; 2018; 12(1):5-11. PubMed ID: 29452917
    [No Abstract]   [Full Text] [Related]  

  • 54. Breaking the chains of lipoprotein lipase deficiency: A pediatric perspective on the efficacy and safety of Volanesorsen.
    den Hollander B; Brands MM; Nijhuis IJM; Doude van Troostwijk LJAE; van Essen P; Hofsteenge GH; Koot BG; Müller AR; Tseng LA; Stroes ESG; van de Ven PM; Wiegman A; van Karnebeek CDM
    Mol Genet Metab; 2024 May; 142(1):108347. PubMed ID: 38401382
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
    Julve J; Escolà-Gil JC; Rotllan N; Fiévet C; Vallez E; de la Torre C; Ribas V; Sloan JH; Blanco-Vaca F
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.
    Ramms B; Patel S; Nora C; Pessentheiner AR; Chang MW; Green CR; Golden GJ; Secrest P; Krauss RM; Metallo CM; Benner C; Alexander VJ; Witztum JL; Tsimikas S; Esko JD; Gordts PLSM
    J Lipid Res; 2019 Aug; 60(8):1379-1395. PubMed ID: 31092690
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study.
    Arca M; Hsieh A; Soran H; Rosenblit P; O'Dea L; Stevenson M
    Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):537-546. PubMed ID: 29889589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering.
    Ramms B; Patel S; Sun X; Pessentheiner AR; Ducasa GM; Mullick AE; Lee RG; Crooke RM; Tsimikas S; Witztum JL; Gordts PL
    JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35653195
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. APOC3 siRNA and ASO therapy for dyslipidemia.
    Chebli J; Larouche M; Gaudet D
    Curr Opin Endocrinol Diabetes Obes; 2024 Apr; 31(2):70-77. PubMed ID: 38334488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.